Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy
| Autor: | Jennifer C. Davis, Robert Darren Brooks, Frankie A. Holmes, Ragene Rivera, Steven J. Ketchel, Nicole L. Hartung, Lina Asmar, Joanne L. Blum, Jean Kochis, Sreeni Chittoor, Donald A. Richards, Des Ilegbodu, Thomas Whittaker, Angel G. Negron, John Pippen, Stephen E. Jones, J. Cantrell, James H. Bordelon, Svetislava J. Vukelja, Joyce O'Shaughnessy |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Time Factors Breast Neoplasms chemistry.chemical_compound Breast cancer Double-Blind Method Exemestane Hot flash Surveys and Questionnaires Internal medicine Multicenter trial Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans Vaginal bleeding Aged Aged 80 and over Gynecology business.industry Middle Aged medicine.disease Androstadienes Menopause Tamoxifen Treatment Outcome Oncology chemistry Chemotherapy Adjuvant Hot Flashes Quality of Life Female medicine.symptom business Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 25:4765-4771 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2007.10.8274 |
| Popis: | Purpose Hormonal breast cancer treatment increases menopausal symptoms in women. This study investigated differences between the symptoms associated with either adjuvant tamoxifen or exemestane. Patients and Methods Ten common symptoms were assessed by self-report questionnaire administered to 1,614 consecutive patients at baseline and every 3 months during the first year of a double-blind, randomized trial of postmenopausal women with early hormone receptor–positive breast cancer. Symptoms were categorized as none, mild, moderate, or severe. A hot flash score was calculated at each time point. Symptoms were analyzed by repeated-measures analysis of variance. Each time period was tested repeatedly against the baseline; an overall P value was assigned for each reported symptom. Results Compliance was excellent, with 7,286 questionnaires analyzed. Baseline symptom prevalence ranged from 2% (vaginal bleeding) to 60% to 70% (bone/muscle aches and low energy). There were no significant differences in vaginal bleeding, mood alteration, or low energy. Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001). Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03). In both groups, the hot flash score peaked at 3 months and decreased thereafter. At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane. Conclusion At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping. Symptoms were common in both groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|